A table comparing three different trials - BELINDA, TRANSFORM, and ZUMA-7 - by three categories: median event-free survival (months), completely response rate, and two-year survival rate. Each category is subdivided into CAR T-cell therapy and standard treatment. TRANSFORM has the highest median event-free survival (months) amount, with 10.1 in the CAR T-cell therapy subcategory. It also has the highest complete response rates, with 66% and 39% for each subcategory. BELINDA and TRANSFORM have “not reached” for both categories in the two-year survival rate, leaving ZUMA-7 with 61% and 52% respectively.